Is NSRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for NSRX. It does not provide personalized investment advice.

NSRX (Nasus Pharma Ltd.) Stock Analysis - Financials

Nasus Pharma Ltd. (NSRX) is a publicly traded the market company. As of July 28, 2026, NSRX trades at $3.09 with a market cap of $36.54M and a P/E ratio of 0.00. NSRX moved -0.96% today. Year to date, NSRX is -58.80%; over the trailing twelve months it is flat. Its 52-week range spans $1.98 to $9.99. Rallies surfaces NSRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are NSRX's key financials?

NSRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NSRX recently traded at $3.09. Market cap is $36.54M. P/E ratio is 0.00. Revenue is $0.

NSRX Key Metrics

Key financial metrics for NSRX
Metric	Value
Price	$3.09
Market Cap	$36.54M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$9.99
52-Week Low	$1.98
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

NSRX Analyst Consensus

NSRX analyst coverage data. Average price target: $0.00.

Common questions about NSRX

What are NSRX's key financials?: NSRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. NSRX recently traded at $3.09. Market cap is $36.54M. P/E ratio is 0.00. Revenue is $0.
Is NSRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for NSRX. It does not provide personalized investment advice.